Ralliant (NYSE:RAL) Upgraded to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Ralliant (NYSE:RAL) from a hold rating to a strong-buy rating in a report released on Monday morning.

Other equities research analysts also recently issued reports about the company. Zacks Research upgraded Ralliant from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, June 30th. Morgan Stanley lifted their target price on Ralliant from $68.00 to $85.00 and gave the stock an “overweight” rating in a report on Tuesday, June 23rd. Citigroup boosted their target price on Ralliant from $81.00 to $82.00 and gave the company a “buy” rating in a research report on Friday. Weiss Ratings restated a “sell (d)” rating on shares of Ralliant in a report on Monday, May 4th. Finally, Evercore started coverage on Ralliant in a report on Tuesday, June 9th. They set an “outperform” rating and a $80.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $75.70.

Ralliant Stock Down 0.5%

Shares of NYSE RAL opened at $65.06 on Monday. The firm’s 50-day moving average price is $67.27 and its 200-day moving average price is $54.44. The company has a current ratio of 1.52, a quick ratio of 1.00 and a debt-to-equity ratio of 0.75. The stock has a market capitalization of $7.28 billion, a price-to-earnings ratio of -6.00, a P/E/G ratio of 2.69 and a beta of 1.61. Ralliant has a 12-month low of $37.27 and a 12-month high of $75.41.

Ralliant (NYSE:RAL) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.63 by $0.05. The firm had revenue of $567.80 million during the quarter. Ralliant had a negative net margin of 56.38% and a positive return on equity of 14.97%. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. On average, equities research analysts anticipate that Ralliant will post 2.88 EPS for the current fiscal year.

Ralliant Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th were paid a $0.05 dividend. The ex-dividend date of this dividend was Monday, June 8th. This represents a $0.20 annualized dividend and a yield of 0.3%. Ralliant’s dividend payout ratio (DPR) is presently -1.84%.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Dodge & Cox lifted its stake in shares of Ralliant by 13.3% during the 4th quarter. Dodge & Cox now owns 12,214,679 shares of the company’s stock worth $621,849,000 after acquiring an additional 1,434,376 shares during the last quarter. Viking Global Investors LP bought a new position in Ralliant in the 2nd quarter valued at $257,200,000. Millennium Management LLC grew its position in Ralliant by 172.4% in the 4th quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock valued at $253,175,000 after acquiring an additional 3,147,660 shares during the last quarter. State Street Corp purchased a new stake in Ralliant in the second quarter worth $213,096,000. Finally, Invesco Ltd. increased its stake in Ralliant by 4.9% in the fourth quarter. Invesco Ltd. now owns 4,059,588 shares of the company’s stock worth $206,674,000 after purchasing an additional 187,898 shares during the period.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.